S

Sutter Health | Center of Excellence in Diabetes and Endocrinology

Research site

(Unclaimed)

Location

3814 Auburn Blvd, suite 72,, Sacramento, California, United States of America

Site insights

Top conditions

Top treatments

Tirzepatide

Ertugliflozin

PF-04971729

somatrogon

BMF-219

MK-8835-059

Vosoritide

Genotropin

LUM-201

MK-8835

Parent organization

This site is a part of Sutter Health

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 11 total trials

A Phase 2 Study of Vosoritide in Children with Idiopathic Short Stature

The purpose of this study is to evaluate i) the effect of multiple doses of vosoritide and ii) the effect of the therapeutic dose of vosoritide compa...

Enrolling

Idiopathic Short Stature

Drug: Human Growth Hormone

Drug: Placebo

A Study of Pitolisant in Patients with Prader-Willi Syndrome

This is a Phase 3, randomized, double-blind, placebo-controlled, multicenter, global clinical study to assess the efficacy and safety of pitolisant i...

Enrolling

Prader-Willi Syndrome

Other: Placebo tablet

Drug: Pitolisant tablet

A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)

The goal of the study is to assess how tirzepatide impacts bodyweight and cardiovascular risk factors when used in conjunction with healthy nutrition...

Enrolling

Weight Gain

Obesity

Drug: Tirzepatide

Drug: Placebo

Ertugliflozin Type 2 Diabetes Mellitus (T2DM) Pediatric Study (MK-8835/PF-04971729) (MK-8835-059)

This study will evaluate the safety and efficacy of ertugliflozin (MK-8835) in pediatric participants with T2DM on metformin with/without insulin. Th...

Active, not recruiting

Type 2 Diabetes Mellitus

Biological: Insulin

Drug: Placebo to ertugliflozin 5 mg